相关实验视频

Updated: Jul 11, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

选择的悖论:在复发性/耐药性扩散性大B细胞淋巴瘤中进行序列治疗

Taylor R Brooks¹, Paolo F Caimi²

¹Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States of America.

|November 10, 2023

概括

对复发性或耐火性扩散性大B细胞淋巴瘤 (DLBCL) 的新疗法提供了希望. 本综述详细介绍了最近的批准,并提供了一个框架,用于对这些复杂疗法进行测序,以获得更好的患者结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

自2017年以来,复发性或耐火性 (R/R) 扩散性大B细胞淋巴瘤 (DLBCL) 的治疗环境迅速发展.
在过去的十年中,美国食品和药物管理局对R/R DLBCL治疗的多项批准已经出现.
自主干细胞移植 (HDT-ASCT) 的高剂量治疗是适合移植的患者的标准,但其他患者的选择有限.

研究的目的:

审查最近批准的R/R DLBCL的第二线和后续线药物.
总结关于这些新疗法的使用现实世界的数据.
为R/R DLBCL.提供一个测序处理的框架.

主要方法:

对R/R DLBCL治疗的最近FDA批准的审查.
关于新型药物的使用现实数据的摘要.
开发治疗序列的临床框架.

主要成果:

目前对R/R DLBCL有众多的治疗选择,包括单克隆抗体,抗体-药物合体,双特异性抗体和化学抗原受体 (CAR) T 细胞.
化学抗原受体 (CAR) T细胞疗法越来越多地被用作早期复发或耐火性DLBCL的二线治疗.
临床益处因患者和疾病特征以及先前的治疗方法而异.

结论:

由于缺乏直接比较和既定的测序策略,对R/R DLBCL的扩大治疗选择存在挑战.
提出了一个框架,以指导临床医生选择和测序疗法,以优化患者的治疗结果.
需要进行进一步的研究,以建立基于证据的共识,以确定最佳治疗序列.

关键词:

双特异性抗体双特异性抗体在CART-T中,我们可以使用CAR-T.DLBCL DLBCL 是一个字母.复发 / 耐火性复发 / 耐火性移植移植移植移植

更多相关视频

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Next-generation Sequencing

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....